39 articles - From Friday Jan 13 2023 to Friday Jan 20 2023
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Ann Oncol |
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Blood |
Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation. Finally, integrated microbiome and metabolome analyses uncovered that FMT reshaped gut microbiota construction and metabolite landscape, and Lachnospiraceae and tryptophan-associated metabolites promoted the recovery of hematopoiesis and rejuvenated aged HSCs. Together, our study highlights the paramount importance of the gut microbiota in HSC aging and provides insights into therapeutic strategies for aging-related hematologic disorders. |
Metabolism in stem cell driven leukaemia: parallels between haematopoiesis and immunity. These studies also offer detailed mechanisms that have yet to be investigated in leukaemia. Given that cancer (and normal) cells can meet their energy requirements by not only upregulating metabolic pathways, but also utilising systemically available substrates, we aim to inform how interlinked these metabolic pathways are, both within leukaemic cells and between cancer cells and their niche. |
Patients with Asian-type DEL can safely be transfused using RhD-positive blood. Therefore, we recommend considering D+ RBC transfusion and discontinuing anti-D prophylaxis in Asian-type DEL patients, including pregnant women. This clinical trial is registered at as NCT03727230. |
Prior Immunization to an Intracellular Antigen Enhances Subsequent Red Blood Cell Alloimmunization in Mice. Using a mouse model of donor RBCs expressing two distinct alloantigens, we demonstrate that immune priming to an intracellular antigen, which would not be detected by any currently used RBC compatibility assays, can directly influence alloantibody formation following exposure to a subsequent distinct surface RBC alloantigen. These findings suggest a previously under-appreciated mechanism whereby transfusion recipient responders may exhibit an increased rate of alloimmunization due to prior immune priming toward intracellular antigens. |
| Blood Cancer J |
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma. The HR for PFS with ixazomib- vs placebo-based therapy was 0.68 in patients with t(4; 14) (95% CI: 0.48-0.96; mPFS 22.4 vs 13.2 months), and 0.77 for patients with amp1q21 (95% CI: 0.63-0.93; mPFS 18.8 vs 14.5 months). A PFS benefit was demonstrated with ixazomib- vs placebo-based therapy regardless of cytogenetic status, with greatest benefit observed in patients with t(4; 14) and amp1q21. |
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Thus, pevonedistat combined with ibrutinib demonstrated safety and promising early efficacy in NHL and CLL. NAE inhibition downregulated NF |
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma. These include CD138, transcription factors such as MYC, and transcription factor 3 (TCF3), which we establish as a novel determinant in MM pathobiology through functional and genomic validation. Our preclinical data therefore provide evidence that blockade of prolyl-aminoacylation evokes a complex pro-apoptotic response beyond the canonical integrated stress response and establish a framework for its evaluation in a clinical setting. |
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. The risk of SPMs was higher in CLL patients who received anti-neoplastic therapy (SIR, 2.12; 95% CI, 1.96-2.28), as compared with those who did not (SIR, 1.58; 95% CI, 1.53-1.63). Routine surveillance activities and tailored interventions to counteract the increased morbidity and excess mortality associated with SPMs are essential for improving long-term outcomes in CLL patients. |
| CA Cancer J Clin |
Cancer statistics, 2023. This progress increasingly reflects advances in treatment, which are particularly evident in the rapid declines in mortality (approximately 2% annually during 2016 through 2020) for leukemia, melanoma, and kidney cancer, despite stable/increasing incidence, and accelerated declines for lung cancer. In summary, although cancer mortality rates continue to decline, future progress may be attenuated by rising incidence for breast, prostate, and uterine corpus cancers, which also happen to have the largest racial disparities in mortality. |
| Haematologica |
E3-ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia. Mechanistically, we found that ubiquitin-mediated degradation of CDK8 was impaired by TRIM31 deletion, which further induced transcriptional expression of PBX1 and Cyclin D1. Taken together, these findings reveal the function of TRIM31 in regulation of hematopoietic stem cell homeostasis and leukemia initiation; and indicate the physiological importance of TRIM31 in leukemia development at early stage of disease. |
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study. Three patients have died, two due to Covid-19 and 1 to tumor lysis syndrome. The first report of the VERITAS study shows that frontline VenR was associated with a high rate of CRs and durable responses with uMRD in young patients with CLL and unfavorable genetic characteristics. |
Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma. In addition, cases with loss of B2M, HLA I and/or HLA II protein expression on the tumor cells also had a low T-cell proportion, providing evidence that lack of these proteins allows for immune evasion. Overall, our results show that patients with DLBCL with a low T-cell proportion in the TME have a poor survival when treated with R-CHOP and exhibit mechanisms of immune escape. |
TAL1 activation in T-Cell acute lymphoblastic leukemia: A novel oncogenic 3' neoenhancer. Here, we demonstrate that this mutation leads to increased enhancer activity, gain of active epigenetic marks and TAL1 activation via recruitment of MYB. These results highlight the diversity of non-coding mutations that can drive oncogene activation. |
| Leukemia |
The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes. This is accompanied by a de-differentiation phenotype that could be reversed by modulating levels of several direct and indirect downstream mediators. Finally, the association of KDM5C levels with long-term disease-free survival of female AML patients emphasizes the clinical relevance of our findings and identifies KDM5C as a novel female-biased tumor suppressor in AML. |
| Thromb Haemost |
P2Y12 Inhibition Suppresses Proinflammatory Platelet-Monocyte Interactions. Objectives To analyze the effect of platelets on monocyte activation and APT on MPA and platelet-induced monocyte activation. Methods Agonist-stimulated whole blood was incubated in the presence of P-selectin, PSGL1, PAR1, P2Y inhibition attenuates platelet-induced monocyte activation. |
Post-PCI Risk Assessment by Inflammation Activity According to Disease Acuity and Time from Procedure. Risk phenotype of hsCRPbaseline correlates with 1-month outcomes only in AMI patients. Whereas the prognostic implication of this risk phenotype appears similar during the late phase, irrespective of the disease acuity. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Blood |
| Haematologica |
Aspirin in essential thrombocythemia: To whom? What formulation? What regimen? Although additional data on gastrointestinal tolerability will be useful, the bid regimen could already be implemented in clinical practice, considering its favorable risk/benefit profile. However, patients whose platelet count has been normalized could still be treated with the od regimen, because they would otherwise be unnecessarily exposed to a potential small risk of gastrointestinal discomfort. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Blood |
| Blood Adv |
| CA Cancer J Clin |
| Leukemia |
Letters to the editors and authors’ replies
| Am J Hematol |
| Blood Cancer J |